Arrowhead Pharmaceuticals Inc. (ARWR)
58.84
-0.08 (0.14%)
Upcoming Events
Latest Headlines
Arrowhead Pharma (ARWR) PT Raised to $109 at UBS
October 15, 2026 9:12 AM - StreetInsider
Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald on ARO-MAPT Ph1 Data
October 15, 2026 7:57 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)
October 15, 2026 6:59 AM - StreetInsider
Arrowhead jumps as breakthrough Alzheimer’s drug clears brain barrier
October 14, 2026 8:13 AM - StreetInsider
Arrowhead drug cuts tau levels 73% in early trial data
October 14, 2026 7:30 AM - StreetInsider
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
October 14, 2026 7:30 AM - BizWire
FDA grants Arrowhead's plozasiran entry into STAR pilot program
October 7, 2026 7:30 AM - StreetInsider
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
October 7, 2026 7:30 AM - BizWire
Arrowhead Pharmaceuticals to hold ARO-MAPT webinar Oct. 14
September 29, 2026 7:30 AM - StreetInsider
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
September 29, 2026 7:30 AM - BizWire
Goldman Sachs Assumes Arrowhead Pharma (ARWR) at Neutral
September 24, 2026 5:00 AM - StreetInsider
Arrowhead reports early data for dual-gene RNAi therapy ARO-DIMER-PA
September 15, 2026 7:31 AM - StreetInsider
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
September 15, 2026 7:30 AM - BizWire
Citi Starts Arrowhead Pharma (ARWR) at Buy
September 8, 2026 1:50 AM - StreetInsider
Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
September 1, 2026 9:07 AM - StreetInsider
Stifel Reiterates Buy Rating on Arrowhead Pharma (ARWR)
August 31, 2026 9:21 AM - StreetInsider
RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
August 31, 2026 8:40 AM - StreetInsider
Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data
August 30, 2026 11:30 AM - StreetInsider
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
August 30, 2026 11:30 AM - BizWire
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
August 24, 2026 7:30 AM - BizWire
Form 4 ARROWHEAD PHARMACEUTICAL For: Aug 18 Filed by: OLUKOTUN ADEOYE Y
August 20, 2026 5:26 PM - SEC Filing
Form 4 ARROWHEAD PHARMACEUTICAL For: Aug 18 Filed by: PERRY MICHAEL S
August 20, 2026 5:22 PM - SEC Filing
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: OLUKOTUN ADEOYE Y
August 18, 2026 5:34 PM - SEC Filing
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: PERRY MICHAEL S
August 18, 2026 5:25 PM - SEC Filing
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
August 17, 2026 9:33 AM - BizWire
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: Avoro Capital Advisors LLC
August 14, 2026 9:01 AM - SEC Filing
Arrowhead Pharma (ARWR) PT Raised to $104 at Stifel
August 5, 2026 8:19 AM - StreetInsider
Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 16c
August 4, 2026 4:26 PM - StreetInsider
Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 16c
August 4, 2026 4:11 PM - StreetInsider
Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 04
August 4, 2026 4:03 PM - SEC Filing
Form 10-Q ARROWHEAD PHARMACEUTICAL For: Jun 30
August 4, 2026 4:03 PM - SEC Filing
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
August 4, 2026 4:01 PM - BizWire
Arrowhead buys FDA priority review voucher for plozasiran sNDA
August 4, 2026 4:00 PM - StreetInsider
Arrowhead Pharmaceuticals buys FDA priority review voucher for plozasiran
August 4, 2026 4:00 PM - StreetInsider
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
August 4, 2026 4:00 PM - BizWire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 3, 2026 4:30 PM - BizWire
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
July 31, 2026 11:21 AM - SEC Filing
Arrowhead Pharma (ARWR) PT Raised to $123 at B.Riley
July 30, 2026 8:47 AM - StreetInsider
Arrowhead Pharma (ARWR) PT Raised to $100 at RBC Capital
July 29, 2026 6:29 AM - StreetInsider
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: BlackRock, Inc.
July 27, 2026 4:27 PM - SEC Filing
Arrowhead completes enrollment in Phase 3 HoFH drug trial
July 27, 2026 7:30 AM - StreetInsider
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
July 27, 2026 7:30 AM - BizWire
Arrowhead Pharma (ARWR) PT Raised to $115 at H.C. Wainwright
July 27, 2026 6:47 AM - StreetInsider
Full Article List
